https://www.ncbi.nlm.nih.gov/pubmed/29201174 NAFLD

Exp Ther Med. 2017 Nov;14(5):4737-4744. doi: 10.3892/etm.2017.5128. Epub 2017 Sep 19.

Zhou H, Shi T, Yan J, Chen X, Liao L, Zhao S, Fang H, Zhuang R.

Abstract
Non-alcoholic fatty liver disease (NAFLD) in children has become the most common liver disease influencing adolescent health and one of the most influencing chronic liver diseases among children in Chinese wealthy families, particularly in coastal regions. However, the medicine available for the treatment of NAFLD is deficient. In order to solve this problem, our team studied the activated carbon N-acetylcysteine (NAC) sustained-release microcapsule, which improves the oxidation resistance, bioavailability and drug stability of acetylcysteine and reduces toxic and side effects. In addition, it accords with the characteristics of medication in infants and children. The present study mainly discusses whether the activated carbon NAC sustained-release microcapsule has effects on dipeptidyl peptidase IV (DPPIV) activity and protein in young rats with NAFLD, and whether it has the effect of an DPPIV inhibitor, hoping to provide new thoughts and methods with respect of basic studies on young rats with NAFLD/non-alcoholic steatohepatitis.

KEYWORDS:
N-acetylcysteine; activated carbon; dipeptidyl peptidase IV; microcapsule; non-alcoholic fatty liver